» Articles » PMID: 24561247

Patterns of Care, Predictors, and Outcomes of Chemotherapy in Elderly Women with Early-stage Uterine Carcinosarcoma: a Population-based Analysis

Overview
Journal Gynecol Oncol
Date 2014 Feb 25
PMID 24561247
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the patterns of care, predictors, and impact of chemotherapy on survival in elderly women diagnosed with early-stage uterine carcinosarcoma.

Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify women 65 years or older diagnosed with stage I-II uterine carcinosarcomas from 1991 through 2007. Multivariable logistic regression and Cox-proportional hazards models were used for statistical analysis.

Results: A total of 462 women met the eligibility criteria; 374 had stage I, and 88 had stage II uterine carcinosarcomas. There were no appreciable differences over time in the percentages of women administered chemotherapy for early stage uterine carcinosarcoma (14.7% in 1991-1995, 14.9% in 1996-2000, and 17.9% in 2001-2007, P=0.67). On multivariable analysis, the factors positively associated with receipt of chemotherapy were younger age at diagnosis, higher disease stage, residence in the eastern part of the United States, and lack of administration of external beam radiation (P<0.05). In the adjusted Cox-proportional hazards regression models, administration of three or more cycles of chemotherapy did not reduce the risk of death in stage I patients (HR: 1.45, 95% CI: 0.83-2.39) but was associated with non-significant decreased mortality in stage II patients (HR: 0.83, 95% CI: 0.32-1.95).

Conclusions: Approximately 15-18% of elderly patients diagnosed with early-stage uterine carcinosarcoma were treated with chemotherapy. This trend remained stable over time, and chemotherapy was not associated with any significant survival benefit in this patient population.

Citing Articles

Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma.

Bharathan R, Polterauer S, Lopez-Sanclemente M, Trukhan H, Pletnev A, Heredia A J Pers Med. 2024; 14(2).

PMID: 38392588 PMC: 10890673. DOI: 10.3390/jpm14020155.


Carcinosarcomas of the Uterus: Prognostic Factors and Impact of Adjuvant Treatment.

Beckmann K, Selva-Nayagam S, Olver I, Miller C, Buckley E, Powell K Cancer Manag Res. 2021; 13:4633-4645.

PMID: 34140809 PMC: 8203298. DOI: 10.2147/CMAR.S309551.


Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study.

Comert G, Turkmen O, Boyraz G, Yalcin I, Altin D, Karalok A Balkan Med J. 2019; 36(4):229-234.

PMID: 30873825 PMC: 6636652. DOI: 10.4274/balkanmedj.galenos.2019.2018.12.75.


Review of Recommended Treatment of Uterine Carcinosarcoma.

Menczer J Curr Treat Options Oncol. 2015; 16(11):53.

PMID: 26374341 DOI: 10.1007/s11864-015-0370-4.


A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Dickson E, Vogel R, Gehrig P, Pierce S, Havrilesky L, Secord A Gynecol Oncol. 2015; 139(2):275-82.

PMID: 26348313 PMC: 5189638. DOI: 10.1016/j.ygyno.2015.09.002.


References
1.
Randall M, Filiaci V, Muss H, Spirtos N, Mannel R, Fowler J . Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 24(1):36-44. DOI: 10.1200/JCO.2004.00.7617. View

2.
Nurgalieva Z, Liu C, Du X . Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer. Int J Gynecol Cancer. 2009; 19(8):1314-21. DOI: 10.1111/IGC.0b013e3181b7662d. View

3.
Zhu J, Sharma D, Gray S, Chen A, Weeks J, Schrag D . Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012; 307(15):1593-601. PMC: 3418968. DOI: 10.1001/jama.2012.454. View

4.
Greer B, Koh W, Abu-Rustum N, Bookman M, Bristow R, Campos S . Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009; 7(5):498-531. DOI: 10.6004/jnccn.2009.0035. View

5.
Ramsey S, Howlader N, Etzioni R, Donato B . Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol. 2004; 22(24):4971-8. DOI: 10.1200/JCO.2004.05.031. View